Orchestra BioMed Holdings Inc Stock Price, News & Analysis

Orchestra BioMed (Nasdaq: OBIO) reported Q3 2025 results and secured $147.6 million in gross proceeds and committed capital from strategic transactions and equity offerings to fund pivotal programs. Cash and marketable securities were $95.8 million as of Sept 30, 2025, with additional $30.0 million received Nov 7, 2025 and commitments of $35.0 million from Ligand and Medtronic by May 1, 2026. Company extended runway into Q4 2027 to support BACKBEAT and the Virtue SAB pivotal trial.

Clinical progress includes initiated enrollment in the Virtue SAB randomized IDE pivotal trial and BACKBEAT protocol enhancements; Q3 operating cash use was $14.9M and net loss was $20.8M (Q3 2025).

Orchestra BioMed (Nasdaq: OBIO) will host a business update call on Wednesday, November 12, 2025 at 8:00 AM ET. The company said the call will cover recent clinical, strategic and financing developments, including an additional strategic investment and collaboration expansion with Medtronic, a new strategic capital relationship with Ligand, a right of first refusal agreement with Terumo, acceleration of enrollment in the BACKBEAT pivotal study of AVIM Therapy, and initiation of patient enrollment in the Virtue SAB US pivotal IDE coronary trial.

Conference details: Toll Free 877-407-9039; International 201-689-8470; Conference ID 13756518; webcast available at https://viavid.webcasts.com/starthere.jsp?ei=1738644&tp_key=c80bc7995c.

Orchestra BioMed (Nasdaq: OBIO) entered into a termination and right of first refusal agreement with Terumo on Oct 28, 2025 for Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for coronary artery disease.

Key terms: Terumo pays an upfront $10 million for ROFR and will invest an additional $20 million via non‑voting preferred stock convertible into common at a minimum of $12 per share, for total proceeds of $30 million. The ROFR supersedes the prior distribution agreement and gives Terumo first review rights on third‑party offers in the global coronary market. Orchestra BioMed retains development and distribution rights in all indications. Orchestra has initiated patient enrollment in the U.S. pivotal IDE Virtue Trial for coronary in‑stent restenosis. Transactions are expected to close no later than Nov 7, 2025.

Orchestra BioMed (NASDAQ: OBIO) announced first patient enrollments in the U.S. pivotal IDE Virtue Trial for the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), a non-coated sirolimus delivery system. The randomized head-to-head study will compare Virtue SAB to the AGENT paclitaxel-coated balloon for coronary in-stent restenosis (ISR).

The trial plans to randomize 740 patients across up to 75 U.S. centers with enrollment completion currently planned for mid-2027. Virtue SAB holds FDA Breakthrough Device Designation for coronary ISR, small vessel disease and below-the-knee PAD. Prior SABRE pilot results cited: 12-month TLF 2.8%, zero TLR from 12–36 months, and 6-month late lumen loss 0.12mm. Orchestra BioMed estimates a >$10 billion global DCB market opportunity.

Orchestra BioMed (NASDAQ: OBIO) will present AVIM Therapy clinical data in a keynote on October 10, 2025 at the Georgia Innovation Summit.

The presentation highlights a strategic collaboration with Medtronic, FDA Breakthrough Device designation for uncontrolled hypertension, an estimated U.S. population of 7.7 million, and a pacemaker-indicated global population of > 750,000 annually.

Key clinical results cited: MODERATO I 24-hour aSBP −11.6 mmHg (1 day) and −10.1 mmHg (3 months); MODERATO II 24-hour aSBP −15.6 mmHg (1 day) and −11.1 mmHg (6 months) with office systolic −17.5 mmHg at 24 months. Reports note improved diastolic measures, favorable hemodynamics, sustained BP reduction, and reversible effect on deactivation.

Orchestra BioMed (NASDAQ:OBIO) presented new clinical data for its AVIM (atrioventricular interval modulation) therapy at HRX 2025, demonstrating significant long-term blood pressure management capabilities. The study showed sustained blood pressure reductions averaging 8.9 mmHg over 3.6 years in patients from the MODERATO II trial.

Key findings revealed that AVIM's effects are sustainable, reversible, and reproducible. The therapy showed no rebound hypertension upon deactivation and demonstrated immediate effectiveness upon reactivation after a 7-day washout period. Orchestra BioMed has partnered with Medtronic (NYSE:MDT) to develop this therapy, targeting an estimated global population of over 750,000 patients indicated for a pacemaker with uncontrolled hypertension.

The therapy has received FDA Breakthrough Device Designation for treating uncontrolled hypertension in high cardiovascular risk patients, addressing an estimated U.S. population of over 7.7 million patients.

Orchestra BioMed (NASDAQ:OBIO) has published significant clinical data in JACC: Clinical Electrophysiology demonstrating the effectiveness of their AVIM therapy for treating uncontrolled hypertension. The pressure-volume loop study showed statistically significant reductions in systolic blood pressure of 17.1-19.2 mmHg compared to standard pacing.

The study, conducted in collaboration with Medtronic (NYSE:MDT), revealed favorable hemodynamic effects in pacemaker patients. Key findings include significant decreases in end-diastolic volume, end-systolic volume, and cardiac workload. The therapy demonstrated effectiveness with both right ventricular and conduction system pacing lead placements.

AVIM therapy has received FDA Breakthrough Device Designation and targets a substantial market of over 7.7 million U.S. patients with uncontrolled hypertension and increased cardiovascular risk, including approximately 750,000 annual pacemaker recipients worldwide who also have hypertension.

Orchestra BioMed (NASDAQ:OBIO) has published significant clinical data in JACC: Advances regarding their AVIM (atrioventricular interval modulation) therapy. The study focused on patients with hypertension and diastolic dysfunction (DD), key contributors to heart failure with preserved ejection fraction (HFpEF).

The MODERATO II study demonstrated that AVIM therapy reduced systolic blood pressure by 12.1±12.8 mmHg in office measurements and 8.3±9.7 mmHg in ambulatory measurements over 6 months. Importantly, patients showed significant improvements in diastolic function markers, with e′ increasing from 5.9±2.0 to 8.8±3.4 cm/sec and E/A ratio improving from 0.86±0.39 to 1.60±0.84.

The therapy is currently being evaluated in the BACKBEAT global pivotal study in collaboration with Medtronic for potential U.S. regulatory approval in pacemaker-indicated patients with uncontrolled hypertension.

Orchestra BioMed (NASDAQ:OBIO) reported Q2 2025 financial results and significant business developments. The company secured $111.2 million in total proceeds through strategic transactions and equity offerings, including $71 million from Medtronic and Ligand. This funding is expected to extend their cash runway into H2 2027.

Key regulatory achievements include FDA Breakthrough Device Designation for AVIM therapy, expanded enrollment criteria approval for the BACKBEAT study, and IDE approval for the Virtue SAB U.S. pivotal trial. Q2 2025 financial results showed revenue of $0.8 million, with a net loss of $19.4 million ($0.50 per share). Cash position as of August 12, 2025, stood at $101 million.